1170 related articles for article (PubMed ID: 10561026)
21. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Naparstek E
Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
23. Rituximab in autologous stem cell transplantation for follicular lymphoma.
Schmitz N
Anticancer Drugs; 2001 Jun; 12 Suppl 2():S21-4. PubMed ID: 11508933
[TBL] [Abstract][Full Text] [Related]
24. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
[TBL] [Abstract][Full Text] [Related]
25. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation.
Kiss JE; Rybka WB; Winkelstein A; deMagalhaes-Silverman M; Lister J; D'Andrea P; Ball ED
Bone Marrow Transplant; 1997 Feb; 19(4):303-10. PubMed ID: 9051238
[TBL] [Abstract][Full Text] [Related]
26. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
[TBL] [Abstract][Full Text] [Related]
27. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
[TBL] [Abstract][Full Text] [Related]
28. Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice.
Vantelon JM; Koscielny S; Brault P; Bourhis JH; Ribrag V; Pico J; Fenaux P; Munck JN
Bone Marrow Transplant; 2000 Mar; 25(5):495-9. PubMed ID: 10713625
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
[TBL] [Abstract][Full Text] [Related]
30. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
31. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
[TBL] [Abstract][Full Text] [Related]
32. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma.
Haas R; Ehrhardt R; Witt B; Goldschmidt H; Hohaus S; Pförsich M; Ehrlich H; Färber L; Hunstein W
Bone Marrow Transplant; 1993 Dec; 12(6):643-9. PubMed ID: 7511017
[TBL] [Abstract][Full Text] [Related]
33. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients.
Benekli M; Hahn T; Shafi F; Qureshi A; Alam AR; Czuczman MS; Bernstein ZP; Chanan-Khan AA; Becker JL; McCarthy PL
Bone Marrow Transplant; 2003 Jul; 32(2):139-43. PubMed ID: 12838277
[TBL] [Abstract][Full Text] [Related]
34. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
35. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
Pavone V; Gaudio F; Guarini A; Perrone T; Zonno A; Curci P; Liso V
Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
[TBL] [Abstract][Full Text] [Related]
36. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas.
Brice P; Divine M; Marolleau JP; Haioun C; Dalcortivo L; Sitthy X; Beaujean F; Norol F; Benbunan M; Reyes F
Bone Marrow Transplant; 1994 Jul; 14(1):51-5. PubMed ID: 7524907
[TBL] [Abstract][Full Text] [Related]
37. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
39. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
40. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
